Recro Pharma, Inc.

62 articles about Recro Pharma, Inc.

• Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26 Conference Call and Webcast Scheduled for Friday, February 26 at 4:30 p.m. Eastern Time

  2/19/2021

  Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that the company will release financial results for the fourth quarter and year-end 2020 after the market close on Friday, February 26, 2021.

• 

  BioSpace Movers & Shakers, Feb. 12

  2/12/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Recro Strengthens Leadership Team With Key Executive and Board Appointments

  2/11/2021

  Recro Pharma, Inc. (“Recro”; NASD: REPH), a dedicated contract development and manufacturing organization (CDMO) solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the continued strengthening of its leadership through key appointments to its management team and board of directors

• Recro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020Conference Call and Webcast Scheduled for Monday, November 9, 2020 at 8:00 a.m. ET

  11/2/2020

  Recro Pharma, Inc. announced that it will report third quarter 2020 financial results on Monday, November 9, 2020.

• Recro to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020Conference Call and Webcast Scheduled for Monday, August 10, 2020 at 8:00 a.m. ET

  8/6/2020

  Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced that it will report second quarter 2020 financial results on Monday, August 10, 2020. Recro’s management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, August 10

• Recro Reports First Quarter 2020 Financial Results and Provides Update on COVID-19 Response and Impact

  5/11/2020

  Recro Pharma, Inc., a leading contract development and manufacturing organization, with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, reported financial results for the three months ended March 31, 2020.

• Recro to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 11, 2020

  5/8/2020

  Recro Pharma, Inc. a leading contract development and manufacturing organization, with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, announced that it will report first quarter 2020 financial results on Monday, May 11, 2020.

• Recro Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters

  5/1/2020

  Recro Pharma, Inc. announced that due to the emerging health impact of the coronavirus pandemic, the Company has changed the location of its 2020 Annual Meeting of Stockholders to its corporate headquarters at 490 Lapp Road, Malvern, Pennsylvania 19355.

• Recro Reports Financial Results for the Year Ended 2019

  3/4/2020

  Recro Pharma, Inc. (Nasdaq:REPH), a high-performing, revenue generating contract development and manufacturing organization (CDMO), today reported financial results for the year ended December 31, 2019.

• Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization

  11/21/2019

  Recro Capitalizing on Strong and Growing CDMO Business

• Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement

  11/13/2019

  Separation of Baudax Bio as Independent Company Expected to be Completed With Distribution on November 21, 2019

• Recro Pharma Reports Third Quarter 2019 Financial Results

  11/8/2019

  Recro Pharma, Inc. (NASDAQ:REPH), a pharmaceutical company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today reported financial results for the three and nine months ended September 30, 2019.

• Recro Pharma’s Board of Directors Approves Separation of Acute Care Business Segment and Declares Special Dividend Distribution of Baudax Bio Common Stock

  11/5/2019

  Recro Pharma, Inc. announced that its board of directors has approved the planned spin-off of its Acute Care business segment, which will be known as Baudax Bio, Inc. and declared a special dividend distribution of all outstanding shares of Baudax Bio common stock.

• Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019Conference Call and Webcast Scheduled for Friday, November 8, 2019 at 8:00 a.m. ET

  11/5/2019

  Recro Pharma, Inc. announced that it will report third quarter financial results on Friday, November 8, 2019. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Friday, November 8, 2019 to discuss the financial results and recent operational highlights..

• FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application

  10/31/2019

  Received Positive Response from FDA Regarding IV Meloxicam Formal Dispute Resolution Request

• 

  Recro Pharma to Lay Off 50 Following Second FDA Rejection for Non-Opioid Pain Treatment

  4/5/2019

  The Pennsylvania-based company disagrees with the FDA's analysis of its clinical data and will seek to work with the agency for approval.
• 

  FDA Action Alert: Sage, Jazz, Lexicon and Sanofi, AMAG Pharma, and Recro Pharma

  3/18/2019

  It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.

• Recro Pharma Provides Regulatory Update for IV Meloxicam

  9/12/2018

  Company Anticipates NDA Resubmission by the End of September 2018

• Recro Pharma Announces Key Sales Team Additions

  2/2/2018

  The company appointed seven new employees focused in the areas of regional sales leadership, marketing and reimbursement.

• Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Data in the Journal of Clinical Pharmacology

  1/17/2018

  The Phase II trial was designed to evaluate the efficacy, safety and tolerability of a single administration of IV meloxicam (15mg, 30mg and 60mg) compared with oral ibuprofen 400mg and placebo following dental impaction surgery.